These findings, researchers wrote, suggest that artificial sweeteners "should not be considered a healthy and safe alternative to sugar."

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

Researchers tracked data from more than 2,000 patients, noting that surgical bailout, infective endocarditis and paravalvular leak were the most common reasons for surgery to be required after TAVR. The full study was published in the American Journal of Cardiology.

The company can now update its labeling instructions for the device to include a new 45-day dual anti-platelet therapy treatment option when treating non-valvular atrial fibrillation. 

Overall, PCI patients appear to face a higher risk of in-hospital mortality, 30-day mortality and in-hospital cardiovascular mortality if they present with an active or historical cancer diagnosis. The group's analysis included data from nearly 6.6 million patients.

A new meta-analysis of 28 different studies confirmed that robotic-assisted radical nephrectomy with IVC thrombectomy is a safe treatment option for kidney cancer.

The new guidance offers a validation template that can assist test developers in submitting an Emergency Use Authorization (EUA) request.